Skip to content
TTM Q1 '26TTM Q4 '25TTM Q3 '25TTM Q2 '25TTM Q1 '25
-$45.61M-6.7%-$42.76M+6.8%-$45.86M+3.0%-$47.3M+0.1%-$47.35M+1.2%
$141K-2.1%$144K-4.6%$151K+1.3%$149K0.0%$149K+1.4%
$6.17M+19.0%$5.19M+9.1%$4.75M+9.7%$4.33M+6.3%$4.07M+13.5%
-$45.3M-7.6%-$42.09M+4.4%-$44.01M-3.1%-$42.68M-3.4%-$41.27M-7.9%
-$67.19M+28.6%-$94.11M-7.7%-$87.37M-204%-$28.77M
$112.53M-7.0%$121.01M-29.7%$172.2M-1.9%$175.55M+150%$70.22M+14.2%
$38K+100%-$15.18M-137%$40.82M-60.8%$104.1M+1,771%$5.56M+227%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where does Trevi Therapeutics, Inc.'s cash flow data come from?
Every line is extracted from Trevi Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.